CYSTOGRAFIN- diatrizoate meglumine injection, solution
BRACCO DIAGNOSTICS INC
Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light.
Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.
Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin should be administered to a pregnant woman only if clearly needed.
If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.
Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.
Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below.
Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full.
|USE DILUTED SOLUTIONS IMMEDIATELY|
|100 mL Bottle|
|Sterile Water or Sterile Saline Added||% Diatrizoate Meglumine w/v||% Organically Bound Iodine w/v||Total Volume|
|0 mL||30.0||14.1||100 mL|
|25 mL||24.0||11.3||125 mL|
|50 mL||20.0||9.4||150 mL|
|67 mL||18.0||8.5||167 mL|
|300 mL Bottle|
|Sterile Water or Sterile Saline Added|
|0 mL||30.0||14.1||300 mL|
|50 mL||25.7||12.1||350 mL|
Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively.
|Revised April 2018|
diatrizoate meglumine injection, solution
|Labeler - BRACCO DIAGNOSTICS INC (849234661)|
|Registrant - BRACCO DIAGNOSTICS INC (849234661)|
|PATHEON ITALIA SPA||434078638||MANUFACTURE(0270-0149) , ANALYSIS(0270-0149)|
|Justesa Imagen, S.A.U||477020325||API MANUFACTURE(0270-0149)|